CTSO

CTSO

Cytosorbents Corporation Common Stock

$1.090+-0.000 (-0.000%)

Prix en Temps Réel

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$1.090

Haut

$1.090

Bas

$1.090

Volume

0.01M

Fondamentaux de l'Entreprise

Statistiques de Trading

Actualités Connexes

PR Newswire

CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...

Voir plus
CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025
Analyst Upgrades

D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents with a Buy and maintains $10 price target.

Voir plus
D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
Analyst Upgrades

HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target

HC Wainwright & Co. analyst Sean Lee reiterates CytoSorbents with a Neutral and maintains $1 price target.

Voir plus
HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target
PR Newswire

CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...

Voir plus
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update
Analyst Upgrades

D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents with a Buy and maintains $10 price target.

Voir plus
D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target